Detalhe da pesquisa
1.
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Gynecol Oncol
; 181: 162-169, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211393
2.
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Future Oncol
; 19(25): 1709-1714, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381977
3.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143970
4.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602290
5.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
6.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Future Oncol
; 17(29): 3781-3785, 2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427115
7.
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Invest New Drugs
; 38(5): 1601-1604, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31907737
8.
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Gynecol Oncol
; 157(1): 36-45, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001076
9.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
N Engl J Med
; 375(22): 2154-2164, 2016 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717299
10.
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Gynecol Oncol
; 152(3): 459-464, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30876489
11.
Efficacy and safety of niraparib as maintenance treatment in older patients (≥â¯70â¯years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 152(3): 560-567, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30638768
12.
Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome.
Int J Gynecol Pathol
; 38(2): 189-195, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29406447
13.
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Lancet Oncol
; 19(8): 1117-1125, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30026000
14.
Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Int J Gynecol Cancer
; 28(8): 1592-1599, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30247250
15.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
16.
Corrigendum to "Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes" [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36-45].
Gynecol Oncol
; 167(2): 399, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850594
17.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
18.
Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.
Int J Gynecol Cancer
; 27(9): 1819-1825, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28930809
19.
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Br J Cancer
; 114(4): 417-26, 2016 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26882065
20.
Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Int J Gynecol Cancer
; 26(3): 431-6, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26807643